abstract BACKGROUND: Since mid-2006, human papillomavirus (HPV) vaccination has been recommended for females aged 11 to 12 years and through 26 years if not previously vaccinated.
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WHAT'S KNOWN ON THIS SUBJECT:
Previous studies have found declines in vaccine type human papillomavirus (HPV) prevalence and genital warts among young females in the United States after introduction of the HPV vaccination program.
WHAT THIS STUDY ADDS:
This study extends previous observations of quadrivalent HPV vaccine impact and examines cross-protection. Within 6 years of vaccine introduction, there were decreases in national vaccine type HPV prevalence of 64% and 34% among females aged 14 to 19 years and 20 to 24 years, respectively.
by guest on February 28, 2016 Downloaded from Three prophylactic human papillomavirus (HPV) vaccines are available, and they have been shown in clinical trials to have high efficacy for prevention of HPV vaccine-type infection and associated disease. [1] [2] [3] The bivalent vaccine targets HPV-16 and -18; the quadrivalent vaccine (4vHPV) targets HPV-6, -11, -16, and -18; and the 9-valent vaccine (9vHPV), licensed at the end of 2014, targets HPV-6, -11, -16, and -18 as well as 5 additional HPV types (31, 33 , 45, 52, and 58). HPV vaccination has been recommended for females in the United States since mid-2006 and for males since 2011 4 ; through 2014, almost all vaccines used were 4vHPV. 5 Routine vaccination is recommended for females and males aged 11 or 12 years and for females through age 26 years and males through age 21 years if not previously vaccinated. Although rates of HPV vaccination have been increasing in the United States, coverage is still low; in 2013, a national survey found that 57% of 13-to 17-year-old females had received at least 1 dose and 38% had received 3 doses. 5 Despite this moderate coverage, data from NHANES exhibited a 56% decrease in 4vHPV type prevalence among females aged 14 to 19 years in the first 4 years of the vaccine era (2007-2010) compared with the prevaccine era. 6 The present report analyzes data from the 4 most recent years available from NHANES (2009) (2010) (2011) (2012) and compares HPV prevalence with the prevaccine era (2003) (2004) (2005) (2006) . In these more recent years, vaccine coverage was higher than in the first 4 years of the vaccine era evaluated previously. 6, 7 We also explore vaccine effectiveness, by analyzing HPV prevalence according to report of vaccination, herd effects, and potential cross-protection against non-4vHPV types. 
METHODS

Survey Design and Population
Specimen Collection and Laboratory Methods
Females aged 14 to 59 years who were examined in an MEC were asked to self-collect a cervicovaginal sample. 8, 9 Extractions and testing were performed at the CDC as previously described. 9 Briefly, extracted DNA was tested by using the Research Use Only Linear Array HPV Genotyping Test (Roche Molecular Diagnostics, Indianapolis, IN) with supplementary HPV-52 quantitative polymerase chain reaction, as previously described. 9 This assay uses L1 consensus polymerase chain reaction followed by type-specific hybridization for qualitative detection of 37 HPV types (6, 11, 16, 18, 26, 31, 
Data Analysis
The 2 most recent NHANES cycles of the vaccine era (2009-2010 and 2011-2012) were combined to achieve stable estimates. HPV type categories investigated include any of 37 HPV types, 4vHPV types (6, 11, 16 , and 18), 4vHPV high-risk types (16 and 18) , any non-4vHPV types, non-4vHPV highrisk types (31, 33, 35 , 39, 45, 51, 52, 56, 58, 59, 66, and 68), 3 high-risk types (31, 33, and 45) for which some cross-protection has been suggested 10, 11 ; and the 5 additional high-risk types in 9vHPV (31, 33, 45, 52, and 58). 3 In analyses limited to sexually active females aged 14 to 24 years, we compared lifetime sex partners and race/ethnicity according to vaccination status in the vaccine era and compared these data with data from the prevaccine era. Vaccine effectiveness was evaluated for prevention of vaccine type HPV detection in 2009-2012; vaccination was defined as report of at least 1 HPV vaccine dose.
All estimates were weighted by using sample weights to account for unequal probabilities of selection and adjustment for nonresponse. 12 Variance estimates were calculated by using a Taylor series linearization to account for the complex survey design. 13 Logit confidence intervals (CIs) were calculated for prevalence estimates, with an α of .05. Prevalence estimates with a relative SE (RSE) >30% or based on <10 cases are noted; these are considered unstable and should be interpreted with caution. We calculated prevalence ratios, adjusted prevalence ratios (aPRs), and their 95% CIs, adjusted for race/ethnicity (non-Hispanic black, non-Hispanic white, Mexican American, and other), and lifetime and past year number of sex partners. Because data on past year sex partners were not available for 14-to 17-yearolds in 2003 to 2004, this variable was not included in some models. The prevalence ratio was the predicted probability calculated from the logistic regression model by using the PREDMARG statement in SAS-Callable SUDAAN. 14 Tables 5 and 6 ).
RESULTS
HPV Prevalence Among All Females
HPV Prevalence Among Sexually Active Females Aged 14 to 24 Years, Overall and According to Vaccination History
Analyses according to vaccination history were limited to sexually active females aged 14 to 24 years, combining the 2 age groups (14-19 years and 20-24 years) in which declines in 4vHPV type prevalence were observed between the prevaccine and vaccine eras. Compared with the prevaccine era (58.4%), in the vaccine era, a larger percentage of females aged 14 to 24 years overall (67.7%) and those unvaccinated (70.0%) reported ≥3 lifetime sex partners (Table 3) . There were no statistically significant differences in race/ethnicity (percent non-Hispanic white shown in Table  3 ). Any HPV type prevalence was similar in the prevaccine era (54.4%) and the vaccine era (58.1%) ( (Table 4 ). There were no statistically significant differences between vaccinated and unvaccinated females in the prevalence of any HPV; non-4vHPV high-risk types; HPV-31, -33, -45; or the 5 additional 9vHPV types.
DISCUSSION
In this study of HPV prevalence in cervicovaginal specimens from a nationally representative sample of females in the United States, we extend our previous findings of vaccine impact with 2 additional years of data from NHANES. 6 Our analysis using the 4 most recent years of data from the vaccine era (2009) (2010) (2011) (2012) showed that among all females aged 14 to 19 years and 20 to 24 years, 4vHPV type prevalence decreased 64% and 34%, respectively, compared with the prevaccine era. There was no statistically significant change in prevalence of any HPV or other categories of HPV types in these age groups and no decline in 4vHPV type prevalence among females aged 24 to 29 years or 30 to 34 years. Data are for all females, including those who did not report having had sex. aPR was adjusted for race/ethnicity and lifetime and past year sex partners (14-to 19-year-old age group not adjusted for past year partners). Non-4vHPV high-risk (HR) includes types -31, -33, -35, -39, -45, -51, -52, -56, -58, -59, -66, and -68. 4vHPV includes types -6, -11, -16, and -18. PR, prevalence ratio. *P < .05; **P < .01 obtained by using the logistic regression model. a RSE >30%. by guest on February 28, 2016 Downloaded from found that 44% of women aged 19 to 21 years and 28% aged 22 to 26 years reported receipt of at least 1 dose of HPV vaccine. 15 In NHANES 2009-2012, 33% of women aged 20 to 24 years reported receipt of at least 1 dose.
In addition to our analysis of prevalence overall in the prevaccine and vaccine eras, we estimated vaccine effectiveness and explored herd effects and potential crossprotection among sexually active 14-to 24-year-olds. High vaccine effectiveness was found for prevention of 4vHPV types within the vaccine era (89%) and there was a large decline in prevalence among those vaccinated compared with the overall prevalence in the prevaccine era (18.6% to 2.1%). Among those unvaccinated, 4vHPV type prevalence was 18.6% in the prevaccine era and 16.9% in the vaccine era; any HPV prevalence remained stable. In our previous analysis, using data from the first 4 years of the vaccine era, it was difficult to assess herd effects because there were differences in sexual behavior and lower prevalence of any HPV type among those unvaccinated compared with the prevaccine era. 6 In the present analysis, a similar percentage of vaccinated and unvaccinated females reported >3 lifetime lifetime sex partners as well as prevalence of any HPV type. Although we cannot claim evidence of herd effects in this analysis, herd effects have been observed for both genital warts and 4vHPV type prevalence in countries in which higher vaccination coverage has been achieved. 16, 17 We also examined the prevalence of 3 HPV types for which there has been some evidence of crossprotection. 10, 11 The prevalence estimate for any HPV-31, -33, -45 in the vaccine era among all female subjects aged 14 to 19 years was unstable; there was no statistically significant decline compared with the prevaccine era. We also found no vaccine effectiveness against these 3 types among females aged 14 to 24 years in the vaccine era. Prelicensure clinical trials of both quadrivalent and bivalent vaccines investigated cross-protection against persistent infection and cervical intraepithelial neoplasia due to nonvaccine high-risk types. 10, [18] [19] [20] Trials of bivalent HPV vaccine found more evidence of crossprotection than did trials of 4vHPV. Other postlicensure prevalence evaluations have investigated crossprotection. 16, 21, 22 In England and Scotland, where the bivalent HPV vaccine was introduced, decreases were observed in HPV-16, -18, as well as related types, in the vaccine era. 21, 22 In Australia, where 4vHPV was introduced, HPV-6, -11, -16, 18 prevalence among women aged 18 to 24 years decreased from 37.6% to 6.5%. 16 For HPV-31, -33, -45, there was no statistically significant change 6 between the prevaccine and vaccine eras; within the vaccine era, however, a significant 58% effectiveness was observed. Further analyses of NHANES data will assess changes in HPV prevalence in the United States as HPV vaccine coverage increases. However, introduction of 9vHPV will make it more difficult to evaluate changes due to potential 4vHPV cross-protection for these 3 types beyond 2015. 23 Finally, we also examined prevalence of the 5 additional 9vHPV types to provide a baseline before potential introduction of this vaccine. In the prevaccine era, the prevalence of any 5 additional types in 9vHPV was 8.4% and 16.5% in females aged 14 to 19 years and 20 to 24 years, respectively, similar to the prevalence of HPV-16 and -18 in those age groups. Of note, these 5 types cause substantially less HPVassociated cancer than HPV-16, -18 because they are less likely to progress to cancer. 24 In the United States, it is estimated that 66% of cervical cancers are attributable to HPV-16 and -18 compared with 15% attributable to the 5 additional 9vHPV types. 25, 26 There was no statistically significant difference in prevalence of the 5 additional 9vHPV types in the prevaccine/vaccine era comparison or in the comparison of vaccinated and unvaccinated sexually active females aged 14 to 24 years within the vaccine era. Although there were some statistically significant differences in prevalence of individual non-4vHPV types between the prevaccine and vaccine eras, these unadjusted comparisons should be interpreted with caution. Prevalence of individual types will continue to be evaluated in future cycles of NHANES.
Limitations of NHANES data have been described. 6 First, vaccination history is by self-report in NHANES, and overreporting or underreporting could have occurred. 27, 28 In the United States, there is wide variation of HPV vaccine coverage by state, with coverage of ≥1 dose ranging from 29% to 73% in 2012. 29 NHANES design does not allow state-specific prevalence estimates; each cycle is designed to include a representative sample of the US population. Third, starting in 2007, adolescents were not oversampled. Some of our analyses were limited by small sample size, and some prevalence estimates were unstable. Although we adjusted the analyses for race/ethnicity and some sexual behaviors, we cannot exclude the possibility of changes or differences in sexual behaviors that were not measured by NHANES.
Ongoing analyses of NHANES will allow monitoring of HPV vaccine impact on HPV prevalence, duration of protection, possible crossprotection, or type replacement. To date, there is no clear indication that type replacement is occurring. Given the low contribution of vaccine types to the overall prevalence of HPV in the population and because co-infections occur, a decrease in any HPV prevalence due to the declines in vaccine type HPV might not be observed, particularly if there is any increase in sexual risk behavior in the population (as we found in women aged 20-24 years).
Our data confirm previous findings of an early impact of HPV vaccination in the United States among females aged 14 to 19 years and extend the findings to females in their early 20s. The decline in vaccine type prevalence after introduction of HPV vaccination is greater than expected based on current 3-dose coverage. This outcome could be due to herd protection or effectiveness of less than a complete 3-dose series, for which there is accumulating evidence. 30, 31 There are now data on population impact of HPV vaccines from many countries 32 ; most reports of declines in HPV vaccine type prevalence are from countries with higher coverage than the United States. 16, 21, 22 Data from NHANES contribute to the increasing body of evidence on HPV vaccine impact and will continue to provide important information as coverage increases and vaccine policy changes in the United States. 23 
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ABBREVIATIONS
4vHPV: quadrivalent HPV vaccine 9vHPV: 9-valent HPV vaccine aPR: adjusted prevalence ratio CDC: Centers for Disease Control and Prevention CI: confidence interval HPV: human papillomavirus MEC: mobile examination center
